Best  ||| S:0 E:5 ||| JJS
practice  ||| S:5 E:14 ||| NN
for  ||| S:14 E:18 ||| IN
the  ||| S:18 E:22 ||| DT
pharmacological  ||| S:22 E:38 ||| JJ
management  ||| S:38 E:49 ||| NN
of  ||| S:49 E:52 ||| IN
hyperthyroid  ||| S:52 E:65 ||| JJ
cats  ||| S:65 E:70 ||| NNS
with  ||| S:70 E:75 ||| IN
antithyroid  ||| S:75 E:87 ||| JJ
drugs  ||| S:87 E:93 ||| NNS
Pharmacological  ||| S:93 E:109 ||| JJ
management  ||| S:109 E:120 ||| NN
of  ||| S:120 E:123 ||| IN
feline  ||| S:123 E:130 ||| JJ
hyperthyroidism  ||| S:130 E:146 ||| NN
offers  ||| S:146 E:153 ||| VBZ
a  ||| S:153 E:155 ||| DT
practical  ||| S:155 E:165 ||| JJ
treatment  ||| S:165 E:175 ||| NN
option  ||| S:175 E:182 ||| NN
for  ||| S:182 E:186 ||| IN
many  ||| S:186 E:191 ||| JJ
hyperthyroid  ||| S:191 E:204 ||| JJ
cats ||| S:204 E:208 ||| NNS
.  ||| S:208 E:210 ||| .
Two  ||| S:210 E:214 ||| CD
drugs  ||| S:214 E:220 ||| NNS
have  ||| S:220 E:225 ||| VBP
been  ||| S:225 E:230 ||| VBN
licensed  ||| S:230 E:239 ||| VBN
for  ||| S:239 E:243 ||| IN
cats  ||| S:243 E:248 ||| NNS
in  ||| S:248 E:251 ||| IN
the  ||| S:251 E:255 ||| DT
last  ||| S:255 E:260 ||| JJ
decade ||| S:260 E:266 ||| NN
:  ||| S:266 E:268 ||| :
methimazole  ||| S:268 E:280 ||| NNS
and  ||| S:280 E:284 ||| CC
its  ||| S:284 E:288 ||| PRP$
pro-drug  ||| S:288 E:297 ||| JJ
carbimazole ||| S:297 E:308 ||| NN
.  ||| S:308 E:310 ||| .
On  ||| S:310 E:313 ||| IN
the  ||| S:313 E:317 ||| DT
basis  ||| S:317 E:323 ||| NN
of  ||| S:323 E:326 ||| IN
current  ||| S:326 E:334 ||| JJ
evidence  ||| S:334 E:343 ||| NN
and  ||| S:343 E:347 ||| CC
available  ||| S:347 E:357 ||| JJ
tablet  ||| S:357 E:364 ||| JJ
sizes ||| S:364 E:369 ||| NNS
,  ||| S:369 E:371 ||| ,
starting  ||| S:371 E:380 ||| VBG
doses  ||| S:380 E:386 ||| NNS
of  ||| S:386 E:389 ||| IN
2Â·5  ||| S:389 E:393 ||| CD
mg  ||| S:393 E:396 ||| NNS
methimazole  ||| S:396 E:408 ||| VBP
twice  ||| S:408 E:414 ||| RB
a  ||| S:414 E:416 ||| DT
day  ||| S:416 E:420 ||| NN
and  ||| S:420 E:424 ||| CC
10  ||| S:424 E:427 ||| CD
to  ||| S:427 E:430 ||| TO
15  ||| S:430 E:433 ||| CD
mg  ||| S:433 E:436 ||| NN
once  ||| S:436 E:441 ||| IN
a  ||| S:441 E:443 ||| DT
day  ||| S:443 E:447 ||| NN
for  ||| S:447 E:451 ||| IN
the  ||| S:451 E:455 ||| DT
sustained  ||| S:455 E:465 ||| JJ
release  ||| S:465 E:473 ||| NN
formulation  ||| S:473 E:485 ||| NN
of  ||| S:485 E:488 ||| IN
carbimazole  ||| S:488 E:500 ||| NNS
are  ||| S:500 E:504 ||| VBP
recommended ||| S:504 E:515 ||| VBN
.  ||| S:515 E:517 ||| .
These  ||| S:517 E:523 ||| DT
doses  ||| S:523 E:529 ||| NNS
should  ||| S:529 E:536 ||| MD
then  ||| S:536 E:541 ||| RB
be  ||| S:541 E:544 ||| VB
titrated  ||| S:544 E:553 ||| VBN
to  ||| S:553 E:556 ||| TO
effect  ||| S:556 E:563 ||| NN
in  ||| S:563 E:566 ||| IN
order  ||| S:566 E:572 ||| NN
to  ||| S:572 E:575 ||| TO
obtain  ||| S:575 E:582 ||| VB
circulating  ||| S:582 E:594 ||| VBG
total  ||| S:594 E:600 ||| JJ
thyroxine  ||| S:600 E:610 ||| NNS
( ||| S:610 E:611 ||| -LRB-
TT4 ||| S:611 E:614 ||| NNP
)  ||| S:614 E:616 ||| -RRB-
concentrations  ||| S:616 E:631 ||| NNS
in  ||| S:631 E:634 ||| IN
the  ||| S:634 E:638 ||| DT
lower  ||| S:638 E:644 ||| JJR
half  ||| S:644 E:649 ||| NN
of  ||| S:649 E:652 ||| IN
the  ||| S:652 E:656 ||| DT
reference  ||| S:656 E:666 ||| NN
interval ||| S:666 E:674 ||| NN
.  ||| S:674 E:676 ||| .
Treated  ||| S:676 E:684 ||| JJ
cases  ||| S:684 E:690 ||| NNS
should  ||| S:690 E:697 ||| MD
be  ||| S:697 E:700 ||| VB
monitored  ||| S:700 E:710 ||| VBN
for  ||| S:710 E:714 ||| IN
side-effects ||| S:714 E:726 ||| NNP
,  ||| S:726 E:728 ||| ,
especially  ||| S:728 E:739 ||| RB
during  ||| S:739 E:746 ||| IN
the  ||| S:746 E:750 ||| DT
first  ||| S:750 E:756 ||| JJ
months  ||| S:756 E:763 ||| NNS
of  ||| S:763 E:766 ||| IN
treatment ||| S:766 E:775 ||| NN
.  ||| S:775 E:777 ||| .
Some  ||| S:777 E:782 ||| DT
side-effects  ||| S:782 E:795 ||| NN
may  ||| S:795 E:799 ||| MD
require  ||| S:799 E:807 ||| VB
discontinuation  ||| S:807 E:823 ||| VBN
of  ||| S:823 E:826 ||| IN
treatment ||| S:826 E:835 ||| NN
.  ||| S:835 E:837 ||| .
At  ||| S:837 E:840 ||| IN
each  ||| S:840 E:845 ||| DT
monitoring  ||| S:845 E:856 ||| NN
visit ||| S:856 E:861 ||| NN
,  ||| S:861 E:863 ||| ,
clinical  ||| S:863 E:872 ||| JJ
condition  ||| S:872 E:882 ||| NN
and  ||| S:882 E:886 ||| CC
quality  ||| S:886 E:894 ||| NN
of  ||| S:894 E:897 ||| IN
life  ||| S:897 E:902 ||| NN
should  ||| S:902 E:909 ||| MD
also  ||| S:909 E:914 ||| RB
be  ||| S:914 E:917 ||| VB
evaluated ||| S:917 E:926 ||| VBN
,  ||| S:926 E:928 ||| ,
with  ||| S:928 E:933 ||| IN
special  ||| S:933 E:941 ||| JJ
attention  ||| S:941 E:951 ||| NN
to  ||| S:951 E:954 ||| TO
possible  ||| S:954 E:963 ||| JJ
development  ||| S:963 E:975 ||| NN
of  ||| S:975 E:978 ||| IN
azotaemia ||| S:978 E:987 ||| NN
,  ||| S:987 E:989 ||| ,
hypertension  ||| S:989 E:1002 ||| NN
and  ||| S:1002 E:1006 ||| CC
iatrogenic  ||| S:1006 E:1017 ||| JJ
hypothyroidism ||| S:1017 E:1031 ||| NN
.  ||| S:1031 E:1033 ||| .
When  ||| S:1033 E:1038 ||| WRB
euthyroidism  ||| S:1038 E:1051 ||| NN
has  ||| S:1051 E:1055 ||| VBZ
been  ||| S:1055 E:1060 ||| VBN
achieved ||| S:1060 E:1068 ||| VBN
,  ||| S:1068 E:1070 ||| ,
monitoring  ||| S:1070 E:1081 ||| VBG
visits  ||| S:1081 E:1088 ||| NNS
are  ||| S:1088 E:1092 ||| VBP
recommended  ||| S:1092 E:1104 ||| VBN
after  ||| S:1104 E:1110 ||| IN
1  ||| S:1110 E:1112 ||| CD
month ||| S:1112 E:1117 ||| NN
,  ||| S:1117 E:1119 ||| ,
3  ||| S:1119 E:1121 ||| CD
months  ||| S:1121 E:1128 ||| NNS
and  ||| S:1128 E:1132 ||| CC
biannually  ||| S:1132 E:1143 ||| JJ
thereafter ||| S:1143 E:1153 ||| NN
.  ||| S:1153 E:1155 ||| .
Cats  ||| S:1155 E:1160 ||| NNS
with  ||| S:1160 E:1165 ||| IN
pre-existing  ||| S:1165 E:1178 ||| JJ
azotaemia  ||| S:1178 E:1188 ||| NNS
have  ||| S:1188 E:1193 ||| VBP
shorter  ||| S:1193 E:1201 ||| JJR
survival  ||| S:1201 E:1210 ||| NN
times ||| S:1210 E:1215 ||| NNS
.  ||| S:1215 E:1217 ||| .
However ||| S:1217 E:1224 ||| RB
,  ||| S:1224 E:1226 ||| ,
development  ||| S:1226 E:1238 ||| NN
of  ||| S:1238 E:1241 ||| IN
mild  ||| S:1241 E:1246 ||| JJ
azotaemia  ||| S:1246 E:1256 ||| NN
during  ||| S:1256 E:1263 ||| IN
the  ||| S:1263 E:1267 ||| DT
initial  ||| S:1267 E:1275 ||| JJ
course  ||| S:1275 E:1282 ||| NN
of  ||| S:1282 E:1285 ||| IN
treatment ||| S:1285 E:1294 ||| NN
,  ||| S:1294 E:1296 ||| ,
unless  ||| S:1296 E:1303 ||| IN
associated  ||| S:1303 E:1314 ||| VBN
with  ||| S:1314 E:1319 ||| IN
hypothyroidism ||| S:1319 E:1333 ||| NN
,  ||| S:1333 E:1335 ||| ,
does  ||| S:1335 E:1340 ||| VBZ
not  ||| S:1340 E:1344 ||| RB
appear  ||| S:1344 E:1351 ||| VB
to  ||| S:1351 E:1354 ||| TO
decrease  ||| S:1354 E:1363 ||| VB
survival  ||| S:1363 E:1372 ||| NN
time ||| S:1372 E:1376 ||| NN
.  ||| S:1376 E:1378 ||| .
The  ||| S:1378 E:1382 ||| DT
long-term  ||| S:1382 E:1392 ||| JJ
effects  ||| S:1392 E:1400 ||| NNS
of  ||| S:1400 E:1403 ||| IN
chronic  ||| S:1403 E:1411 ||| JJ
medical  ||| S:1411 E:1419 ||| JJ
management  ||| S:1419 E:1430 ||| NN
require  ||| S:1430 E:1438 ||| VBP
further  ||| S:1438 E:1446 ||| JJ
study ||| S:1446 E:1451 ||| NN
.  ||| S:1451 E:1453 ||| .
